1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors.
D000230:Adenocarcinoma / Q000188:drug therapy; D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D002817:Chordoma / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004806:Ependymoma / Q000188:drug therapy; D005909:Glioblastoma / Q000188:drug therapy*; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009603:Nitroso Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010689:Phlebitis / Q000139:chemically induced; D011878:Radiotherapy / Q000009:adverse effects; D014508:Urea / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D014508:Urea